Substance P (SP) is an important
neurotransmitter that mediates various gut functions; however, its precise pathophysiological role remains unclear. In this study, we investigated the effect of SP on colonic function and the effect of
TAK-637 [(aR,9R)-7-[3,5-bis(trifluoromethyl)benzyl]-8,9,10,11-tetrahydro-9-methyl-5-(4-methylphenyl)-7H-[1,4]diazocino[2,1-g][1,7]naphthyridine-6,13-dione] a new neurokinin-1 (NK1) receptor antagonist, on colonic responses to SP or stress in Mongolian gerbils. SP and the selective NK1 agonist [pGlu6]SP6-11 significantly increased fecal pellet output.
TAK-637 reduced [pGlu6]SP6-11-induced defecation, but did not significantly affect
neurokinin A-, 5-hydroxytryptamine- or
carbachol-stimulated defecation. Oral
TAK-637 decreased restraint stress-stimulated fecal pellet output with an ID50 value of 0.33 mg/kg.
Ondansetron and
atropine, but not the peripheral
kappa-receptor agonist
trimebutine, also reduced restraint stress-stimulated defecation.
TAK-637 inhibited the increase in fecal pellet output stimulated by intracerebroventricular injection of
corticotropin-releasing factor, but did not affect the stress-induced increase in plasma
adrenocorticotropic hormone levels.
Denervation of the sensory neurons with
capsaicin did not affect stress-stimulated defecation. These results suggest that NK1 receptors in the enteric plexus play an important role in stress-induced changes in colonic function, and that
TAK-637 may be useful in the treatment of functional bowel diseases such as
irritable bowel syndrome.